

## DAFTAR PUSTAKA

1. Perrson F, Rossing P. Diagnosis of diabetic kidney disease : state of the art and future perspective. *International society of nephrology. January 2018. Volume 8, issue 1, pages 2-7*
2. Umanath K, Lewis JB. Update on diabetic nephropathy : core curriculum 2018. *Am J Kidney Dis. 71 (6) : 884-95. 2018.*
3. Wispadji S. Komplikasi kronik diabetes : mekanisme terjadinya, diagnosis dan strategi pengelolaan. *Buku Ajar Ilmu Penyakit Dalam jilid II.* Jakarta, Indonesia: Interna Publishing. 2014:2359-66
4. Kawanami D, Matoba K, Utsonomiya K. Dyslipidemia in diabetic nephropathy. *Renal Replacement Therapy. 2016;16.*  
<https://doi.org/10.1186/s41100-016-0028-0>
5. Makbul A, Soewondo P, Soelistijo S, et al. Pedoman Pengelolaan Dislipidemia di Indonesia. PERKENI 2019
6. Chehade JM, Gladysz M, Mooradianet AD. Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management. *Drugs (2013) 73:327–339.*
7. Lin CF, Chang YH, Chien SC, et al. Epidemiology of dislipidemia in Asia Pasific region. *Int J Geront 2018; 12:2-6.*
8. Mikolasevic I, Žutelija M, Mavrinac V, et al. Dyslipidemia in patients with chronic kidney disease: etiology and management. *Int J Nephrol Renovasc Dis. 2017; 10: 35–45.*

9. Wanner C. Chapter 58 - Dyslipidemia and Chronic Kidney Disease: Trials and Guidelines. *Chronic Renal Disease*. 2015. Pages 706-710.
10. Prakash J. Dyslipidemia in diabetic kidney disease. *Clinical Queries: Nephrology* 0102 (2012) 115–118
11. Sulaiman M. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. *Diabetol Metab Syndr*. 2019; 11: 7
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* . 1998 ; (352) : 837–53.
13. Writing Team for Diabetes Control and Complications Trial/Epidemiology of Diabetic Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. *JAMA*. 2002 ; (287) : 2563–9.
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998 ; (317) : 703–13.
15. Dhafer GA, Muatasim MN, Mohammed AS, et al. Factors affecting albuminuria in diabetic patients at King Fahad Hospital in Almadinah Almunawwarah. *Journal of Taibah Univ Medic Science*. 2015;10 (2) : 250-256.
16. Palazhy S, Viswanathan V. Lipid abnormalities in type 2 diabetes mellitus patient with overt nephropathy. 2017. *Diabetes Metab J* ; (41) : 128-34.

17. Puspallata A, Rajeev P, Sanjay S, et al. Association of serum lipids with diabetic retinopathy in type 2 diabetes. 2013. *Indian J of Endocr Met ; (17) : 1-4.*
18. Marlina T, Tamara P, Ivana PR, et al. Obesity a risk factor for microvascular and neuropathic complications in diabetes. 2003. *Diabetologica ; 32 (2) : 72-79.*
19. Azim UA, Mona MS, Dina OA. Recent Advances in Management of Diabetic Nephropathy. *Clin Exp Nephrol. 2017 ; 2 (2) : 1-22.*
20. Mogensen C, Christensen C, Vittinghus. The Stages in Diabetic Renal disease With Emphasis On The Stage Of Incipient Diabetic Nephropathy. *Diabetes. 1983;( 32) : Suppl 2.*
21. Haneda M, Utsunomiya K, Koya D, et al. A new classification of diabetic nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. JDI. Open acces.
22. Alicic R, Rooney M, Tuttle K. Diabetic Kidney Disease. *CJASN* December 2017, 12 (12) 2032-2045
23. Hendromartono. Nefropati Diabetik. In: Sudoyo AW, Setiyohadi, et al. *Buku Ajar Ilmu Penyakit Dalam jilid II.* Jakarta, Indonesia: Interna Publishing. 2014:2386-94.
24. Kim SS, Jong HK, In JK. Current Challenges in Diabetic Nephropathy : Early Diagnosis and Ways to Improve Outcomes. *Endocrinol Metab. 2016; (31) :245-253.*

25. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int (Suppl)*. 2013; 3: 1–150
26. Chen S, Tseng CH. Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients. *Rev Diabet Stud*. 2013 Summer-Fall; 10(2-3): 88–100.
27. Shoji T, Emoto M, Kawagishi T, et al. Atherogenic lipoprotein changes in diabetic nephropathy. *Atherosclerosis*. 2001 Jun; 156(2):425-33.
28. Yang X, So WY, Ma R, et al. Effects of albuminuria and renal dysfunction on development of dyslipidaemia in type 2 diabetes-the Hong Kong Diabetes Registry. *Nephrol Dial Transplant*. 2008 Sep; 23(9):2834-40.
29. Muntner P, Coresh J, Smith JC, et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. *Kidney Int*. 2000 Jul; 58(1):293-301.
30. Lin J, Hu FB, Rimm EB, et al. The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. *Kidney Int*. 2006 Jan; 69(2):336-42.
31. Jenkins AJ, Lyons TJ, Zheng D, et al. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. *Kidney Int* 2003;64:817-28.
32. Kolhar U, Priyanka P. Study of serum lipid profile in type 2 diabetes mellitus patients and its association with diabetic nephropathy. *Int J Adv Med*. 2017 Dec;4(6):1513-1516

33. Kajingulu FM, Lepira FB, Mbutiwi FI, et al. Albuminuria status and patterns of dyslipidemia among type 2 diabetes black patients managed at tertiary health-care hospital : A Post hoc analysis.
34. Tseng CH. Differential dyslipidemia associated with albuminuria in type 2 diabetic patients in Taiwan. *Clinical Biochemistry* 42 (2009) 1019-1024
35. Soelistidjo SA, Novida H, Rudijanto A, et al. Konsensus Pengelolaan dan Pencegahan Diabetes Melitus tipe 2 di Indonesia. Perkeni 2015.
36. Inoue S, Zimmet P. The Asia Pacific perspective, redefining obesity and it's treatment. *Australia : Helth Communications Australia Pty Limited on behalf of the steering commitee, 2000.*
37. Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas : Global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract.*2011;94(3):311–21.
38. Al-Rubeaan K, Siddiqui K, Al-Ghonaim MA, et al. The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters. *Ann Saudi Med.* 2018 Jan-Feb; 38(1): 46–56
39. Onuigbo J, Unuigbe E, Kalu OA, et al. Prevalence of dyslipidemia among adult diabetic patients with overt diabetic nephropathy in Anambra state South-East Nigeria. *Nigerian Journal of Clinical Practice.*Apr-Jun 2011. Vol 14. Issue 2, page 171-5
40. Yu MK, Lyles CR, Bent-Shaw LA, et al. Risk factor, age and sex differences in chronic kidney disease prevalence in a diabetic cohort: The Pathways Study. *Am J Nephrol.* 2012; 36(3): 245–251.

41. Sanoop M, K Shifa, K Vipindas. Comparative Study of Lipid Profile in Patients with Chronic Kidney Disease on Haemodialysis / Conservative Management with Control Population. *American Journal of Biochemistry*, Vol. 9 No. 2, 2019, pp. 17-20
42. Dash SC, Agarwal SK, Panigrahi A, et al. Diabetes, Hypertension and Kidney Disease Combination "DHKD Syndrome" is common in India. *J Assoc Physicians India*. 2018 Mar;66(3):30-3.
43. Hill CJ, Cardwell CR, Maxwell AP, et al. Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National Diabetes Audit. *An International Journal of Medicine*, Volume 106, Issue 10, October 2013, Pages 933–942
44. Hussain S, Jamali MC, Habib A. Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. *J.Cegh.2020.05.016*
45. Narindrangura P, Bosl W, Ram R, et al. Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in Thailand. *Lipids in Health and Disease* volume 18, Article number: 90 (2019)
46. Ephraim RK, Mantey R, Atombo S, et al. Chronic kidney disease in type 2 diabetes mellitus patients : comparison of KDIGO and KDOQI guidelines. *jajme.2018.07.003*.
47. Zoppini G, Chonchol M, Perrone F. et al. Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. *Nutr Metab Cardiovasc Dis*. 2009 Oct;19(8):580-6.
48. Russo GT, De Cosmo S, Viazzi F, et al. Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2

Diabetes: The AMD Annals Initiative. *Diabetes Care* 2016 Dec; 39(12): 2278-2287.

49. Y. Hossain A, Deb PK, Hossain MA, et al. Correlation between serum cholesterol and serum albumin level in childhood nephrotic syndrome. 2016. *Urol Nephrol Open Access J* 3(4): 00086.

50. HJ Kim, HA Park, YG Cho, et al. Gender Difference in the Level of HDL Cholesterol in Korean Adults. *KJFM*.2011.32.3.173-181.

## Lampiran


 KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN  
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
 KOMITE ETIK PENELITIAN KESEHATAN  
 RSPTN UNIVERSITAS HASANUDDIN  
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
 JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KALIG MAKASSAR 90245.  
 Contact Person: dr. Agussalim Bukhari, M.Med.,Ph.D., Sp.GK. TELP. : 081241850858, 0411 5780103, Fax : 0411-581431

---

**REKOMENDASI PERSETUJUAN ETIK**  
 Nomor : 574/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 22 September 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20060253		No Sponsor	
Peneliti Utama	dr. Cely Norma Palebangan		Sponsor	
Judul Peneliti	Hubungan Antara Laju Filtrasi Glomerulus Dengan Abnormalitas Lipid Plasma Pada Pasien Penyakit Ginjal Diabetik Non Dialis			
No Versi Protokol	2	Tanggal Versi	17 September 2020	
No Versi PSP	2	Tanggal Versi	17 September 2020	
Tempat Penelitian	RSUP Dr.Wahidin Sudirohusodo dan RS Jejangir di Makassar			
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal		Masa Berlaku	Frekuensi review lanjutan
			22 September 2020 sampai 22 September 2021	
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan